
Shares of drug developer Aptevo Therapeutics APVO.O rise 84% to $2.60 premarket
On Wednesday, co in a filing said that hedge fund billionaire Steven Cohen's firm has taken a 9.1% stake in APVO
Point72 Asset Management, founded by Cohen in 2014, now holds 299,944 shares of Aptevo
The firm has shared voting and dispositive power over the shares
On Tuesday, APVO said its experimental cancer therapy led to 100% remission in an early-to-mid stage trial
As of last close, stock down 98% YTD